PFE (Pfizer Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by PFE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-08-17 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-08-12 | ALBERT BOURLA | Chairman & CEO | Buy | — | — |
| 2026-08-06 | JENNIFER B. DAMICO | SVP & Controller | Sell | — | — |
| 2026-08-06 | JENNIFER B. DAMICO | SVP & Controller | Sell | — | — |
| 2026-08-05 | RONALD E BLAYLOCK | Director | Buy | — | — |
| 2026-08-05 | Mortimer J Buckley | Director | Buy | — | — |
| 2026-08-03 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-07-16 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-07-13 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-07-01 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-06-16 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-06-10 | JENNIFER B. DAMICO | SVP & Controller | Sell | — | — |
| 2026-06-01 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-05-18 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-05-04 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-04-27 | Cyrus Taraporevala | Director | A | — | — |
| 2026-04-27 | JAMES C SMITH | Director | A | — | — |
| 2026-04-27 | James Quincey | Director | A | — | — |
| 2026-04-27 | SHANTANU NARAYEN | Director | A | — | — |
| 2026-04-27 | Joseph Echevarria | Director | A | — | — |
| 2026-04-27 | Susan Desmond-Hellmann | Director | A | — | — |
| 2026-04-27 | Mortimer J Buckley | Director | A | — | — |
| 2026-04-27 | RONALD E BLAYLOCK | Director | A | — | — |
| 2026-04-27 | DAN R. LITTMAN | Director | A | — | — |
| 2026-04-27 | JOHNSON SUZANNE M NORA | Director | A | — | — |
| 2026-04-27 | Scott Gottlieb | Director | A | — | — |
| 2026-04-17 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-04-16 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-04-01 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-03-30 | Mortimer J Buckley | Director | A | — | — |
| 2026-03-30 | Joseph Echevarria | Director | A | — | — |
| 2026-03-30 | SHANTANU NARAYEN | Director | A | — | — |
| 2026-03-30 | James Quincey | Director | A | — | — |
| 2026-03-30 | JAMES C SMITH | Director | A | — | — |
| 2026-03-30 | Cyrus Taraporevala | Director | A | — | — |
| 2026-03-16 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-03-05 | Alexandre de Germay | Executive Vice President | A | — | — |
| 2026-03-05 | PAYAL SAHNI | Executive Vice President | A | — | — |
| 2026-03-05 | Michael McDermott | Executive Vice President | A | — | — |
| 2026-03-05 | Lidia Fonseca | Executive Vice President | A | — | — |
| 2026-03-05 | Andrew Baum | Executive Vice President | A | — | — |
| 2026-03-05 | AAMIR MALIK | Executive Vice President | A | — | — |
| 2026-03-05 | DOUGLAS M LANKLER | Executive Vice President | A | — | — |
| 2026-03-05 | David M Denton | Chief Financial Officer & EVP | A | — | — |
| 2026-03-05 | CHRISTOFFEL BOSHOFF | President, R&D | A | — | — |
| 2026-03-05 | ALBERT BOURLA | Chairman & CEO | A | — | — |
| 2026-03-05 | JENNIFER B. DAMICO | SVP & Controller | MIXED | — | — |
| 2026-03-03 | JENNIFER B. DAMICO | SVP & Controller | F | — | — |
| 2026-02-27 | CHRISTOFFEL BOSHOFF | President, R&D | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,347,539 | — |
| — | Executive Chairman | 1,698,272 | — |
| — | Director | 1,265,131 | — |
| — | Former Chairman & CEO | 827,296 | — |
| — | Vice Chairman | 644,118 | — |
| — | Executive Vice President | 615,311 | — |
| — | Executive Vice President | 468,690 | — |
| — | Chairman & CEO | 435,555 | — |
| — | Senior Vice President | 412,019 | — |
| — | Senior Vice President | 397,076 | — |
| — | Group President | 393,236 | — |
| — | Senior Vice President | 389,172 | — |
| — | Senior Vice President | 388,288 | — |
| — | Senior Vice President | 374,234 | — |
| — | Group President | 367,537 | — |
| — | President R&D | 323,710 | — |
| — | Business Unit President | 315,124 | — |
| — | Executive Vice President | 282,071 | — |
| — | Former Exec. Vice President | 280,380 | — |
| — | Senior Vice President | 255,139 | — |
| — | Executive Vice President | 251,732 | — |
| — | Business Unit President | 189,728 | — |
| — | Group President | 184,840 | — |
| — | Executive Vice President | 166,789 | — |
| — | President, R&D | 162,088 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PFE quote page; the site-wide leaderboard is on the insider transactions hub.